麦德特龙公司将以高达5.85亿美元的价格收购以色列公司CathWorks, 获得人工智能心脏诊断技术. Medtronic to buy Israeli firm CathWorks for up to $585M, gaining AI heart diagnostic tech.

Medtronic同意以价值高达5.85亿美元的一笔交易收购以色列医疗设备公司CathWorks公司CathWorks, 行使2022年伙伴关系的一项选择权。 Medtronic has agreed to acquire CathWorks, an Israeli medical device company, in a deal worth up to $585 million, exercising an option from a 2022 partnership. 这项购置将在公平贸易委员会批准之前,将CathWorks的AI-FFRANGio系统(用于评估标准X光的心脏病风险)带入Medtronic的组合中。 The acquisition, pending FTC approval, will bring CathWorks’ AI-powered FFRangio System—used to assess heart disease risk from standard X-rays—into Medtronic’s portfolio. 该技术提供了传统心脏测试以外的非侵入性替代品,使得在程序进行期间能够提供实时诊断数据。 The technology offers a non-invasive alternative to traditional cardiac testing, enabling real-time diagnostic data during procedures. 这笔交易预计将在美敦力2026财政年度结束时结束,标志着该公司首次在软件型心脏诊断方面采取重大举措,并反映出AI在心血管护理方面的日益一体化。 The deal, expected to close by the end of Medtronic’s fiscal 2026, marks the company’s first major move into software-based cardiac diagnostics and reflects growing integration of AI in cardiovascular care.